Brokers Issue Forecasts for C4 Therapeutics FY2030 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Equities research analysts at Brookline Capital Management issued their FY2030 earnings per share (EPS) estimates for shares of C4 Therapeutics in a research report issued on Monday, January 5th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of $40.97 for the year. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03. The firm had revenue of $11.23 million during the quarter, compared to the consensus estimate of $6.28 million. C4 Therapeutics had a negative return on equity of 64.40% and a negative net margin of 395.51%.

A number of other research analysts also recently weighed in on the stock. Cowen initiated coverage on shares of C4 Therapeutics in a research report on Tuesday, December 2nd. They issued a “buy” rating for the company. TD Cowen initiated coverage on C4 Therapeutics in a report on Tuesday, December 2nd. They issued a “buy” rating for the company. Barclays lowered their target price on C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company raised their price target on C4 Therapeutics from $5.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, September 23rd. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.25.

C4 Therapeutics Stock Up 9.4%

NASDAQ CCCC opened at $2.22 on Tuesday. The firm’s 50 day moving average is $2.35 and its 200-day moving average is $2.33. The company has a market capitalization of $215.14 million, a PE ratio of -1.33 and a beta of 2.93. C4 Therapeutics has a 12-month low of $1.09 and a 12-month high of $4.07.

Hedge Funds Weigh In On C4 Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. American Century Companies Inc. increased its position in C4 Therapeutics by 6.9% during the first quarter. American Century Companies Inc. now owns 141,986 shares of the company’s stock worth $227,000 after buying an additional 9,154 shares during the last quarter. Man Group plc boosted its stake in shares of C4 Therapeutics by 15.0% during the 3rd quarter. Man Group plc now owns 90,278 shares of the company’s stock worth $200,000 after acquiring an additional 11,791 shares during the period. Zacks Investment Management acquired a new position in shares of C4 Therapeutics during the 3rd quarter worth approximately $29,000. Invesco Ltd. increased its holdings in shares of C4 Therapeutics by 11.1% during the 2nd quarter. Invesco Ltd. now owns 155,017 shares of the company’s stock worth $222,000 after acquiring an additional 15,531 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in C4 Therapeutics by 0.9% in the 2nd quarter. Bank of America Corp DE now owns 2,008,004 shares of the company’s stock valued at $2,871,000 after acquiring an additional 17,180 shares during the period. Institutional investors own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.